Pneumonia News and Research

Latest Pneumonia News and Research

Researchers demonstrate SARS-CoV-2 infection in human lung bronchioalveolar tissue model

Development of an in vitro human-derived tissue model for studying virus infection and disease progression in the alveolar cells of the lungs responsible for oxygen and carbon dioxide exchange with the blood might enable the study of possible therapies for acute respiratory distress syndrome (ARDS) triggered by SARS-CoV-2.

11 Jan 2021

One ambulance ride leads to another when packed hospitals cannot handle non-covid patients

Keely Connolly thought she would be safe once the ambulance arrived at Hutchinson Regional Medical Center in Kansas.

11 Jan 2021

Researchers receive NIH grant to develop more effective flu vaccines

To build better vaccines, scientists want to know more about how our bodies make adequate numbers of effective, durable antibodies against the influenza virus.

11 Jan 2021

Synthetic lung organoids provide high-throughput platform to identify new cellular targets of SARS-CoV-2

An interesting new study published on the bioRxiv preprint server describes a new platform that allows a high-throughput workflow to generate matched human lung buds in the tens of thousands. This allows researchers to study SARS-CoV-2 infection and therapeutics in lung tissue that mirrors the key aspects of human lung development.

10 Jan 2021

Innovative artistic intervention can help reduce fatal health threat to young African children

The fatal threat from diarrhea and pneumonia to young children in the world's poorer countries can be drastically reduced by using traditional performing arts to encourage mothers to provide youngsters with safe food and water, a new study reveals.

7 Jan 2021

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

7 Jan 2021

Study: Durable immunity against secondary COVID-19 disease is possible in most individuals

Researchers who studied antibody and immune cell responses in more than 180 men and women who had recovered from COVID-19 report these patients' immune memory to the virus - across all immune cell types studied - was measurable for up to 8 months after symptoms appeared.

7 Jan 2021

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) - a rare disease for which there is no FDA-approved first-line therapy.

6 Jan 2021

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.

4 Jan 2021

Sustained immune dysregulation due to COVID-19 in non-hospitalized patients

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path.

29 Dec 2020

Study offers explanation for silent hypoxemia in COVID-19 patients

One of the physiopathological characteristics of COVID-19 that has most baffled the scientific and medical community is what is known as "silent hypoxemia" or "happy hypoxia".

29 Dec 2020

Researchers identify new weapon to battle the rising tide of antibiotic-resistant bacteria

As scientists around the globe wage war against a novel, deadly virus, one University of Colorado Boulder lab is working on new weapons to battle a different microbial threat: a rising tide of antibiotic-resistant bacteria which, if left unchecked, could kill an estimated 10 million people annually by 2050.

23 Dec 2020

Genetic analysis reveals novel traits associated with COVID-19 severity

Researchers in the United States have conducted genetic correlation studies revealing novel traits associated with the development of severe coronavirus disease 2019 (COVID-19).

23 Dec 2020

COVID-19 severity could be linked to genetic variance

A new study describes some potentially important genetic factors in the host that may shape the clinical symptoms and signs of the disease.

23 Dec 2020

Researchers test effects of full doses of anticoagulants in COVID-19 patients

Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients.

23 Dec 2020

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.

23 Dec 2020

Pneumonia News and Research

Latest Pneumonia News and Research

Researchers demonstrate SARS-CoV-2 infection in human lung bronchioalveolar tissue model

One ambulance ride leads to another when packed hospitals cannot handle non-covid patients

Researchers receive NIH grant to develop more effective flu vaccines

Synthetic lung organoids provide high-throughput platform to identify new cellular targets of SARS-CoV-2

Innovative artistic intervention can help reduce fatal health threat to young African children

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

Study: Durable immunity against secondary COVID-19 disease is possible in most individuals

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Sustained immune dysregulation due to COVID-19 in non-hospitalized patients

Study offers explanation for silent hypoxemia in COVID-19 patients

Researchers identify new weapon to battle the rising tide of antibiotic-resistant bacteria

Genetic analysis reveals novel traits associated with COVID-19 severity

COVID-19 severity could be linked to genetic variance

Researchers test effects of full doses of anticoagulants in COVID-19 patients

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Cadmium linked to more severe flu and pneumonia infections

Reston virus causes severe respiratory disease in piglets

Many US health experts underestimated the coronavirus … until it was too late

SARS-CoV-2 RNA in serum associated with poor prognosis and high mortality

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Pneumonia News and Research

Latest Pneumonia News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in